Sanara MedTech Inc. (SMTI)

Market Cap	321.50M
Revenue (ttm)	45.84M
Net Income (ttm)	-7.94M
Shares Out	8.38M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,411
Open	38.52
Previous Close	38.59
Day's Range	38.00 - 39.25
52-Week Range	17.41 - 49.50
Beta	1.89
Analysts	Buy
Price Target	61.20 (+59.46%)
Earnings Date	May 15, 2023

About SMTI

Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: SMTI

Financial Performance

In 2022, Sanara MedTech's revenue was $45.84 million, an increase of 89.87% compared to the previous year's $24.14 million. Losses were -$7.94 million, 0.20% more than in 2021.

Analyst Forecast

According to 7 analysts, the average rating for SMTI stock is "Buy." The 12-month stock price forecast is $61.2, which is an increase of 59.46% from the latest price.

Price Target

$61.2

(59.46% upside)

Analyst Consensus: Buy